CliffBio
small molecule

MEZOFY

ARIPIPRAZOLE

Loss of exclusivityAugust 2033latest FDA-listed patent expiry
CompanyCMG Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameMEZOFY
Active ingredientARIPIPRAZOLE
Strength5MG
Dosage formFILM
RouteORAL
ModalitySmall molecule
FDA approvalApril 2025
Marketing statusDISCN

Listed patents

PatentExpiresType
9694008August 2033product

More from CMG Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MEZOFY patent cliff — loss of exclusivity August 2033 | CliffBio